Company news
Shanghai Micurx Pharmaceutical Co., Ltd. Class A (SSE:688373) news
Shanghai Micurx Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 25, 2026: "SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement…
Press releases & updates
"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Progress of Litigation Involving a U.S. Subsidiary
September 24, 2026
"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Shareholding Reduction Plan of Shareholder
September 22, 2026
"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Expiration of Shareholding Reduction Plan by Shareholder and Results of Shareholding Reduction
September 9, 2026
"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 4, 2026
"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 25, 2026
"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Continued Use of Idle Raised Funds for Cash Management
July 27, 2026
"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Resignation of Securities Affairs Representative
July 7, 2026
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
June 22, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 2, 2026
Announcement on Shareholding Reduction Plan for Shareholders
May 18, 2026
Notice on Convening the 2025 Annual General Meeting
May 12, 2026
Announcement on Expiration of Shareholding Reduction Plan of Shareholder and Results of Shareholding Reduction
May 6, 2026
Announcement on Expiration of Shareholding Reduction Plan of Shareholder and Results of Shareholding Reduction and Change in Equity Reaching 1% Scale
April 30, 2026
Announcement on Resolutions of the 27th Meeting of the 2nd Board of Directors
April 28, 2026
Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
April 24, 2026
Announcement on Postponing Some Investment Projects Financed by Raised Funds
March 27, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 27, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 26, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
February 10, 2026
Announcement on Voluntary Disclosure of Permission Granted by the US for the Initiation of Clinical Trials of MRX-5
January 28, 2026
Earnings Preannouncement for 2025
January 23, 2026
Announcement on Voluntary Disclosure of the Company Certified as a High-tech Enterprise
January 14, 2026
Announcement on Change of Securities Affairs Representative
January 13, 2026
Announcement on Voluntary Disclosure of Compensation for the Patent Protection Period of the Company's Core Products
January 8, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
January 7, 2026
Announcement on Resignation of Directors and Senior Management Members
December 31, 2025
Announcement on Transfer of Some of The Company's Wholly-owned Subsidiary Kerui Kaisi's Business To Four Wholly-owned Subsidiaries Including Kangyue Biology, etc.
November 17, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
November 7, 2025
Announcement on Voluntary Disclosure of the Issuance of Approval Notices for Supplementary Applications for Drugs and Supplementary Applications for Drug Clinical Trials
November 5, 2025
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
November 4, 2025
Report for Q3 2025
October 27, 2025
Notice on the 3rd Extraordinary General Meeting in 2025
October 22, 2025
Announcement on Purchasing Liability Insurance for Directors and Senior Management Members
October 15, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
October 9, 2025
Announcement on Adding Extraordinary Proposal Supplementary Notice of the 2nd Extraordinary General Meeting in 2025
September 24, 2025
Announcement on Absence of Financial Assistance or Compensation Provided to the Investors in the Current Private Placement, Either Directly or Through Interested Parties
September 22, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 5, 2025
Report on the Transfer Result of Shareholders' Inquiry and Indicative Announcement on Change in Equity of Shareholder with Reaching 5% Shares Exceeding Integer Multiple of 5% and 1%
September 4, 2025
Announcement on Voluntary Disclosure of the Approval of Marketing Registration for Contezolid API from New Additional Manufacturer
September 1, 2025
Indicative Announcement on Pricing for Shareholder Inquiry Transfer
August 22, 2025
Shareholder's Inquiry Transfer Plan
August 21, 2025
Announcement on Resignation and Appointment of Deputy General Manager
August 19, 2025
Announcement on Continued Use of Idle Raised Funds Used for Cash Management
August 5, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
July 17, 2025
Announcement on Change of Sponsor Representative
July 15, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
July 1, 2025
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report
June 27, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 5, 2025
Announcement on the Voluntary Disclosure of Acceptance of the New Drug Application for the Marketing Authorization of Contezolid Acefosamil Sodium for Injection
May 21, 2025
Announcement on Convening the Q1 2025 Performance Briefing
May 19, 2025